HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study
A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers
Intrahepatic Cholangiocarcinoma
DRUG: HMPL-453|DRUG: Rabeprazole
PK parameter for HMPL-453: AUC0-t, Area under the concentration time curve from time 0 to the last measurable concentration, Day 1 to Day 33|PK parameter for HMPL-453: AUC0-inf, Area under the concentration time curve from time 0 extrapolated to infinity, Day 1 to Day 33|PK parameter for HMPL-453: Cmax, Maximum observed plasma concentration, Day 1 to Day 33
Assessment of safety procedures findings, Any untoward medical occurrence associated with the study drug, Day 1 to Day 33|PK parameter for HMPL-453: tmax,t1/2, Time to reach the maximum observed plasma concentration, elimination half-life, Day 1 to Day 33
A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers